Observes a tucidinostat-based regimen for newly diagnosed diffuse large B-cell lymphoma
Tracks how a tucidinostat-containing treatment works in adults newly diagnosed with lymphoma.
Plain-language title generated from the registry record
Registry title: A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of DLBCL
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- No. 197 Ruijin 2nd Road, Huangpu District, ShanghaiShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Ruijin Hospital
- Trial code
- NCT06779435
- Record updated
- 19 February 2025
- Original description
This is a prospective, observational, multicenter, cohort study with 400 newly treated DLBCL patients. To evaluate the clinical efficacy and safety of tucidinostat in the real-world treatment of primary diffuse large B-cell lymphomaRead full original descriptionShow less
A Multicenter, Prospective, Real-world Study of a Regimen Containing Tucidinostat for Primary Treatment of Diffuse Large B-cell Lymphoma
This is a prospective, observational, multicenter, cohort study with 400 newly treated DLBCL patients. To evaluate the clinical efficacy and safety of tucidinostat in the real-world treatment of primary diffuse large B-cell lymphoma
Inclusion: 1. Age ≥18 years old, male or female; 2. No previous treatment for DLBCL, including chemotherapy, targeted therapy and immunotherapy; 3. DEL [Diffuse large B-cell lymphoma with double expression of MYC and BCL2 (immunohistochemical MYC≥40%, BCL2≥50%)] was confirmed by pathology; Or non-double expression but at least one of the following:; TP53 or other epigenetic gene mutations (as in: ACTB, BCL6, BCOR, CREBBP, EP300, EZH2, HIST1H1C, HIST1H1E, HIST1H2BK, HIST2H2AB, IRF4, KMT2A, KMT2C, KMT2D, MYC, MYD88, NSD2, RAG1, SETD1B SF3B1, SIN3A, TBL1XR1, TET2, TOX, TP53, TRIP12, TRRAP, UBE2A); MYC and BCL2 double hit; 4. Plan to receive or are receiving a treatment regimen containing tucidinostat (if it is permitted to start using tucidinostat after obtaining specific test results due to pending genetic sequencing results); 5. Voluntarily sign informed consent.
Exclusion: 1. Patients currently enrolled or planning to participate in any interventional clinical trial; 2. The expected survival time is less than 6 months; 3. There are any other reasons that the investigators believe are not suitable for patients to participate in this study.